GLP1_NEW
Efsubaglutide alfa 3 mg injection once weekly
EFSUBA_SC_3MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.05 (-1.49 to -0.60) | 0.80 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.81 (-3.08 to -0.51) | 0.52 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.46 (0.01 to 25.95) | 0.48 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.46 (0.01 to 27.40) | 0.60 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.54 (-12.61 to 11.62) | 0.47 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.99 (0.27 to 3.56) | 0.49 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.94 (0.11 to 6.79) | 0.63 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.88 (0.69 to 5.14) | 0.61 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.55 (1.80 to 22.92) | 0.28 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 6.61 (2.92 to 17.36) | 0.07 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.91 (0.49 to 8.59) | 0.43 |